SPSixtine de Percin

Sixtine de Percin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sixtine de Percin has a total of 166 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Head & Neck and Shoulder Desmoid‐Type Fibromatosis: Presentation and Natural History of These Ultra‐Rare Locations

    by Nicolas Penel, Sylvie Bonvalot, Julien Elices‐Diez, Antoine Italiano, Benjamin Verret, Jean‐Emmanuel Kurtz, Pascale Dubray‐Longeras, Cécile Guillemet, Florence Duffaud, François Bertucci, et al.

    Background: Active surveillance is recommended as the first‐line management for desmoid‐type fibromatosis ( DF ); however, data on DF of the head and neck (H&N) and shoulder regions are limited. Methods: We examined patients with DF located in the H&N and shoulder regions, comparing baseline characteristics and event‐free survival ( EFS ). A subgroup analysis was performed among patients initially managed with active surveillance. Results: H&N accounted for 4% of all DF cases, and shoulder accounted for 5%. Pain (62% vs. 53% and 33%, respectively; p = 0.01) and functional impairment (29% vs. 0% and 6%, respectively; p = 0.002) were significantly more frequent in shoulder DF compared with H&N DF and DF at other sites. Regardless of initial management, the 3‐year EFS rates for H&N and shoulder were similar to those for other locations ( p = 0.74). Among patients initially managed with active surveillance, the 3‐year EFS rates for H&N and shoulder were similar to that for DF at other locations ( p = 0.63). Conclusion: Pain and functional impairment differed significantly by location; however, the outcomes of both H&N and shoulder DF did not differ significantly from those of DF at other locations. Trial Registration: This investigation was registered under the clinical trial registration number NCT02867033

  • Open Access

    Orthopedic Surgical Management of Soft Tissue Sarcomas in a Referral Center: 5-Year Oncological Outcomes

    by Diane Ji Yun Yoon, Pascaline Boudou-Rouquette, Sarah Kreps, Frédérique Larousserie, Valérie Dumaine, Antoine Feydy, Morad Abou Al Ezz, Sixtine de Percin, Virginie Audard, Camille Tlemsani, et al.

  • Open Access

    Supplementals 1 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma

    by Elisabeth Ashton, Valérie Taly, Camille Tlemsani, Pascaline Boudou-Rouquette, Sixtine de Percin, Johanna Noël, Antoine Gaudet-Chardonnet, Francesco Sullo, Béatrice Parfait, Justine Abdelli, et al.

  • Open Access

    Supplemental Data 2 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma

    by Elisabeth Ashton, Valérie Taly, Camille Tlemsani, Pascaline Boudou-Rouquette, Sixtine de Percin, Johanna Noël, Antoine Gaudet-Chardonnet, Francesco Sullo, Béatrice Parfait, Justine Abdelli, et al.

    Supplemental Data 2 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma

  • Open Access

    Supplemental Data 1 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma

    by Elisabeth Ashton, Valérie Taly, Camille Tlemsani, Pascaline Boudou-Rouquette, Sixtine de Percin, Johanna Noël, Antoine Gaudet-Chardonnet, Francesco Sullo, Béatrice Parfait, Justine Abdelli, et al.

    Supplemental Data 1 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma

  • Open Access

    Data from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma

    by Elisabeth Ashton, Valérie Taly, Camille Tlemsani, Pascaline Boudou-Rouquette, Sixtine de Percin, Johanna Noël, Antoine Gaudet-Chardonnet, Francesco Sullo, Béatrice Parfait, Justine Abdelli, et al.

    Purpose:No universal circulating biomarker exists for soft-tissue sarcoma (STS) and bone sarcoma. We report the translational relevance of a Droplet Digital PCR (ddPCR) assay allowing universal, specific, and dynamic detection of sarcoma-related hypermethylated ctDNA.Experimental Design:In silico analysis (The Cancer Genome Atlas/Gene Expression Omnibus datasets, n = 8,330) identified hypermethylated DNA positions in STS/bone sarcoma, unmethylated in nonsarcoma tissues or white blood cells releasing circulating plasma cell-free DNA (cfDNA). A ddPCR assay following bisulfite conversion of cfDNA was developed. The methylation signature performances were evaluated in independent in silico cohorts (The Cancer Genome Atlas/Gene Expression Omnibus, n = 1,342). The ddPCR assay was applied to cfDNA from healthy donors, patients with metastatic STS (METASARC cohort, n = 49, 13 histotypes), and patients with STS/bone sarcoma treated with neoadjuvant chemotherapy (NEOSARC cohort, n = 42, 10 histotypes).Results:A ddPCR assay targeting seven methylated genomic positions distinguished sarcoma samples from nonneoplastic mesenchymal and endothelial/liver tissues (AUC = 0.95; in silico validation set). Sensitivity allowed methylated DNA detection at a 1:1,000 dilution in genomic DNA, with a methylated allele frequency of 0.06%. ctDNA was positively detected in 45% of METASARC (22/49) and 74% of NEOSARC (31/42) patients, across all histotypes. ctDNA detection correlated with poor overall survival in METASARC patients with STS (P = 0.039). Increasing ctDNA during neoadjuvant chemotherapy was associated with poor outcomes in NEOSARC (composite criteria with poor histologic response, radiological progression, or relapse within 6 months; P = 0.0095).Conclusions:This sensitive ddPCR assay for universally methylated ctDNA enables precise detection, prognostication, and real-time monitoring of tumor burden in patients with high-grade and advanced sarcoma, regardless of histotype or origin.

  • Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma

    by Elisabeth Ashton, Valérie Taly, Camille Tlemsani, Pascaline Boudou-Rouquette, Sixtine de Percin, Johanna Noël, Antoine Gaudet-Chardonnet, Francesco Sullo, Béatrice Parfait, Justine Abdelli, et al.

    Purpose: No universal circulating biomarker exists for soft-tissue sarcoma (STS) and bone sarcoma. We report the translational relevance of a Droplet Digital PCR (ddPCR) assay allowing universal, specific, and dynamic detection of sarcoma-related hypermethylated ctDNA. Experimental Design: In silico analysis (The Cancer Genome Atlas/Gene Expression Omnibus datasets, n = 8,330) identified hypermethylated DNA positions in STS/bone sarcoma, unmethylated in nonsarcoma tissues or white blood cells releasing circulating plasma cell-free DNA (cfDNA). A ddPCR assay following bisulfite conversion of cfDNA was developed. The methylation signature performances were evaluated in independent in silico cohorts (The Cancer Genome Atlas/Gene Expression Omnibus, n = 1,342). The ddPCR assay was applied to cfDNA from healthy donors, patients with metastatic STS (METASARC cohort, n = 49, 13 histotypes), and patients with STS/bone sarcoma treated with neoadjuvant chemotherapy (NEOSARC cohort, n = 42, 10 histotypes). Results: A ddPCR assay targeting seven methylated genomic positions distinguished sarcoma samples from nonneoplastic mesenchymal and endothelial/liver tissues (AUC = 0.95; in silico validation set). Sensitivity allowed methylated DNA detection at a 1:1,000 dilution in genomic DNA, with a methylated allele frequency of 0.06%. ctDNA was positively detected in 45% of METASARC (22/49) and 74% of NEOSARC (31/42) patients, across all histotypes. ctDNA detection correlated with poor overall survival in METASARC patients with STS (P = 0.039). Increasing ctDNA during neoadjuvant chemotherapy was associated with poor outcomes in NEOSARC (composite criteria with poor histologic response, radiological progression, or relapse within 6 months; P = 0.0095). Conclusions: This sensitive ddPCR assay for universally methylated ctDNA enables precise detection, prognostication, and real-time monitoring of tumor burden in patients with high-grade and advanced sarcoma, regardless of histotype or origin.


  • Open Access

    Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis

    by Julie Berthet, Amel Kime, Bruno Borghese, Sixtine De Percin, Antoine Gaudet-Chardonnet, Jerome Alexandre, Guillaume Beinse

    Uterine and ovarian carcinosarcomas (OCSs) are rare and aggressive neoplasms. We assessed whether progression free survival after initial treatment (PFS1) was associated with the clinical benefit of chemotherapy after progression, estimated as overall survival (OS) after progression/relapse. All consecutive patients treated with chemotherapy for stage I-IV uterine/OCS in Cochin University Hospital between 2010 and 2022 were included in this retrospective cohort. Association between PFS1 and OS after progressive disease (PD) was determined by Cox regression. Optimal PFS1 threshold for OS after PD prediction was determined by a time-dependent receiver operating characteristic-curve analysis. Forty patients treated for endometrial (n=32) or OCS (n=8) were included. Median PFS1 and OS after PD were 16 months 95% confidence interval (95% CI=11-not available [NA]) and 6 months (95% CI=2-15). In patients who relapsed/progressed (n=20), OS after PD was anticipated by PFS1 (Pearson r=0.61; area under the curve=0.79; 95% CI=0.6-1). At the threshold of PFS1 ≤/>9 months (n=6/n=7), median OS post PD were 2 months (0.1-NA) and 15 months (6-NA), for patients treated with platinum/anthracycline based chemotherapy in second line. Patients receiving best supportive care alone (n=7) had a median OS post PD of 8 months (1.3-NA). Our results highlight that a subgroup of carcinosarcomas patients exhibits a durable benefit from chemotherapy in the relapse settings, and suggest the use of PFS1, as a proxy of platinum-sensitivity, to select patients who might derive higher clinical benefit of a 2nd line of chemotherapy.


  • Open Access

    Differential predictive value of resident memory CD8+T cell subpopulations in patients with non-small-cell lung cancer treated by immunotherapy

    by Léa Paolini, Thi Tran, Stéphanie Corgnac, Jean-Philippe Villemin, Marie Wislez, Jennifer Arrondeau, Ludger Johannes, Jonathan Ulmer, Louis-Victorien Vieillard, Joséphine Pineau, et al.

    Background: A high density of resident memory T cells (TRM) in tumors correlates with improved clinical outcomes in immunotherapy-treated patients. In most clinical studies, TRM are defined by the CD103 marker. However, it is clearly established that not all TRM express CD103, but can be defined by other markers (CD49a, CD69, etc). The frequency of these subpopulations of TRM expressing or not CD103 varies according to the location of the cancer. Little is known about their functionality and their predictive impact on response to immunotherapy. In preclinical models, only some subpopulations of TRM are associated with cancer vaccine efficacy. Methods: Multiparametric cytometry analyses were used to demonstrate the presence of TRM subpopulations in the lung in mice after vaccination and in fresh ex vivo human non-small cell lung cancer (NSCLC). An analysis of the T-cell repertoire of these TRM was conducted to search for their relationships. Multiplex immunofluorescence techniques were used to quantify intratumor infiltration of TRM subpopulations in two cohorts of patients with NSCLC. The impact on the clinical outcome of the TRM tumor infiltration was also investigated. Results: We identified two main TRM subpopulations in tumor-infiltrating lymphocytes derived from patients with NSCLC: one co-expressing CD103 and CD49a (double positive (DP)), and the other expressing only CD49a (simple positive (SP)); both exhibiting additional TRM surface markers like CD69. Despite higher expression of inhibitory receptors, DP TRM exhibited greater functionality compared with SP TRM. Analysis of T-cell receptor (TCR) repertoire and expression of the stemness marker TCF1 revealed shared TCRs between populations, with the SP subset appearing more progenitor-like phenotype. In the training cohort, PD-L1 (Programmed Death-Ligand 1) and TCF1+CD8+T cells predict response to anti-PD-1. In patient with NSCLC validation cohorts, only DP TRM predicted PD-1 blockade response. Multivariate analysis, including various biomarkers associated with responses to anti-PD-(L)1, such as total CD8, TCF1+CD8+T cells, and PD-L1, showed that only intratumoral infiltration by DP TRM remained significant. Conclusions: This study highlights the non-equivalence of TRM subpopulations. The population of TRM co-expressing CD103 and CD49a appears to be the most functional and has the most significant capacity for predicting response to immunotherapy in multivariate analysis in patients with NSCLC.


  • Top Cited Papers
    Open Access

    Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

    by P Harter, C Marth, M-A Mouret-Reynier, C Cropet, D Lorusso, E M Guerra-Alía, T Matsumoto, I Vergote, N Colombo, J Mäenpää, et al.